Business
Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting
Bemnifosbuvir Demonstrated Favorable Overall Nonclinical Safety Profile, Including Lack of Reproductive and Development Toxicity in Animal Models BOSTON,
About this update from Atea Pharmaceuticals, Inc.
[{"type":"text","content":"Bemnifosbuvir Demonstrated Favorable Overall Nonclinical Safety Profile, Including Lack of Reproductive and Development Toxicity in Animal Models\nBOSTON, March 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented two posters highlighting nonclinical data demonstrating the nonclinical safety of bemnifosbuvir (AT-527) at the Society of Toxicology (SOT) 61st Annual Meeting taking place in San Diego, California from March 27 – 31, 2022. Atea’s poster board presentation P857 was selected by the SOT Risk Assessment Specialty Selection Executive Committee as a top ten abstract this year. “We are very pleased with the favorable nonclinical toxicity profile for bemnifosbuvir as evidenced by the results of the studies presented today,” said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea Pharmaceuticals. “We believe the favorable toxicity profile of bemnifosbuvir makes it ideal for clinical development in broad patient populations and in oral combination regimens for the treatment of severe viral infections, such as COVID-19 and hepatitis C.” The following poster boards highlighting the favorable bemnifosbuvir nonclinical safety assessment and toxicology data were presented: Abstract 4793/Poster Board P857: Lack of Reproductive and Developmental Toxicity for AT-527, an Oral Purine Nucleotide Prodrug for COVID-19 Infection presented by Shouqi Luo, Ph.D., Executive Director of Toxicology at Atea and authored by Dr. Luo and other Atea scientists. Highlights of the data showed that: There were no AT-527-related effects on the fertility, reproduction, embryofetal and postnatal development in rats.In rabbits, there were no AT-527-related embryofetal abnormalities at doses up to 100 mg/kg/day even in the presence of evident maternal toxicities at 100 mg/kg/day, i.e., body weight loss, abortions, and mortalities, which were secondary to reduced food consumption.The maternal toxicity of AT-527 in rabbits was confounded by the vehicle which itself resulted in reduced food consumption and body weight loss noted in a 7-day tolerability study in nonpregnant female rabbits. Abstract 4794/Poster Board P858: Characterization of the Toxicity Profile of AT-527, a Novel Guanosine Nucleotide Prodrug with Antiviral Activity for COVID-19 Infectio...